Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2020 Filed May 11, 2020 20:41 UTC |
LUDWIG EDWARD JDirector
|
GrantDeferred Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007402 · doc4.xml · derivative · entry 1 LUDWIG EDWARD J · CIK 0001221783 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,673 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:37 UTC |
JAMES DONNADirector
|
GrantDeferred Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007401 · doc4.xml · derivative · entry 1 JAMES DONNA · CIK 0001197735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,484 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F2 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.underlying_shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:37 UTC |
FUJIMORI YOSHIAKIDirector
|
GrantDeferred Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007400 · doc4.xml · derivative · entry 1 FUJIMORI YOSHIAKI · CIK 0001233160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,111 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. F3 · derivative.exercise_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. F3 · derivative.expiration_date: Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:37 UTC |
Dockendorff Charles JDirector
|
GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007399 · doc4.xml · nonDerivative · entry 1 Dockendorff Charles J · CIK 0001400563 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,099 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:37 UTC |
Connors Nelda JDirector
|
GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007398 · doc4.xml · nonDerivative · entry 1 Connors Nelda J · CIK 0001478748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,990 F1 · shares: Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $185,000 divided by the closing price of common stock on the date of grant. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:20 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionDeferred Stock Units · Derivative | 2,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007000 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,185 Underlying: Common Stock · 2,061 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 1, 2020, the first anniversary of the date of grant. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:20 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Tax withholdingCommon Stock | 626 | $35.99 | $22,529.74 |
DisclosureSEC source: 0001225208-20-007000 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,675 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| May 01, 2020 Filed May 4, 2020 20:20 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionCommon Stock | 2,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007000 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 20:30 UTC |
Pierce David AEVP Pres MedSurg
|
SaleCommon Stock | 14,793 | $38.00 | $562,134.00 |
DisclosureSEC source: 0001225208-20-006612 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,597 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 04, 2020 Filed Mar 5, 2020 21:10 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 1,796 | $38.05 | $68,337.80 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · nonDerivative · entry 3 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,085 F3 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionDeferred Stock Units · Derivative | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004424 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,206 Underlying: Common Stock · 3,603 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Tax withholdingCommon Stock | 1,779 | $37.23 | $66,232.17 |
DisclosureSEC source: 0001225208-20-004424 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,048 Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionCommon Stock | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004424 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionDeferred Stock Units · Derivative | 3,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · derivative · entry 4 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,606 Underlying: Common Stock · 3,303 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Tax withholdingCommon Stock | 1,507 | $37.23 | $56,105.61 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · nonDerivative · entry 2 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,881 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 21:10 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 3,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004422 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:15 UTC |
Pierce David AEVP Pres MedSurg
|
SaleCommon Stock | 3,485 | $38.00 | $132,430.00 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · nonDerivative · entry 3 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,390 F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:15 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,623 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-20-004163 · doc4.xml · derivative · entry 6 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,623 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:15 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 16,763 | $37.47 | $628,183.37 |
DisclosureSEC source: 0001225208-20-004163 · doc4.xml · nonDerivative · entry 4 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,591 F3 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.35 to $37.655, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:15 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 9,623 | $16.31 | $156,951.13 |
DisclosureSEC source: 0001225208-20-004163 · doc4.xml · nonDerivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:13 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 19,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004158 · doc4.xml · derivative · entry 6 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,227 shares Expires 2020-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 2, 2016, the first anniversary of the date of grant. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:13 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 8,720 | $38.27 | $333,714.40 |
DisclosureSEC source: 0001225208-20-004158 · doc4.xml · nonDerivative · entry 4 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,709 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:13 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionCommon Stock | 19,227 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004158 · doc4.xml · nonDerivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:09 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
SaleCommon Stock | 15,783 | $37.21 | $587,220.72 |
DisclosureSEC source: 0001225208-20-004146 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,085 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.61, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionDeferred Stock Units · Derivative | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004167 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,666 Underlying: Common Stock · 1,833 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 1,021 | $37.39 | $38,175.19 |
DisclosureSEC source: 0001225208-20-004167 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,795.99 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 1,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004167 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,816.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:16 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionDeferred Stock Units · Derivative | 1,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004166 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,444 Underlying: Common Stock · 1,222 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:16 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Tax withholdingCommon Stock | 374 | $37.39 | $13,983.86 |
DisclosureSEC source: 0001225208-20-004166 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,671 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:16 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
Exercise / conversionCommon Stock | 1,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004166 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Pierce David AEVP Pres MedSurg
|
Exercise / conversionDeferred Stock Units · Derivative | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,888 Underlying: Common Stock · 2,444 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Pierce David AEVP Pres MedSurg
|
Tax withholdingCommon Stock | 1,109 | $37.39 | $41,465.51 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,875 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Pierce David AEVP Pres MedSurg
|
Exercise / conversionCommon Stock | 2,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004164 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionDeferred Stock Units · Derivative | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004165 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 1,018 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Tax withholdingCommon Stock | 309 | $37.39 | $11,553.51 |
DisclosureSEC source: 0001225208-20-004165 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,240 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionCommon Stock | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004165 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,549 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionDeferred Stock Units · Derivative | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004163 · doc4.xml · derivative · entry 5 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,259 Underlying: Common Stock · 1,629 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Tax withholdingCommon Stock | 808 | $37.39 | $30,211.12 |
DisclosureSEC source: 0001225208-20-004163 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,731 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:15 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 1,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004163 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Exercise / conversionDeferred Stock Units · Derivative | 815 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004162 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,630 Underlying: Common Stock · 815 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Tax withholdingCommon Stock | 241 | $37.39 | $9,010.99 |
DisclosureSEC source: 0001225208-20-004162 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,873 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Exercise / conversionCommon Stock | 815 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004162 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004161 · doc4.xml · derivative · entry 4 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,074 Underlying: Common Stock · 2,037 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 929 | $37.39 | $34,735.31 |
DisclosureSEC source: 0001225208-20-004161 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,787 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004161 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionDeferred Stock Units · Derivative | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004160 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037 Underlying: Common Stock · 1,018 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Tax withholdingCommon Stock | 309 | $37.39 | $11,553.51 |
DisclosureSEC source: 0001225208-20-004160 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,945 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:14 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionCommon Stock | 1,018 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004160 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:13 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 18,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-004159 · doc4.xml · derivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,660 Underlying: Common Stock · 18,330 shares Expires 2022-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:13 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 8,313 | $37.39 | $310,823.07 |
DisclosureSEC source: 0001225208-20-004159 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,219,628 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.